StockNews.com Downgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Sell

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Wednesday.

A number of other brokerages have also recently commented on AGIO. The Goldman Sachs Group upped their price target on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research note on Tuesday, June 4th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $46.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 17th. Finally, Royal Bank of Canada increased their price objective on Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an “outperform” rating in a report on Tuesday, June 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $50.67.

Agios Pharmaceuticals Price Performance

Shares of AGIO opened at $42.02 on Wednesday. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $49.06. The stock’s fifty day moving average price is $39.14 and its two-hundred day moving average price is $31.13. The firm has a market cap of $2.39 billion, a PE ratio of -6.65 and a beta of 0.79.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, topping the consensus estimate of ($1.65) by $0.20. The company had revenue of $8.19 million during the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The firm’s revenue for the quarter was up 46.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.47) EPS. Sell-side analysts anticipate that Agios Pharmaceuticals will post -2.68 earnings per share for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,791 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total value of $214,642.05. Following the transaction, the director now owns 137,396 shares of the company’s stock, valued at $3,785,259.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Deutsche Bank AG grew its stake in Agios Pharmaceuticals by 0.6% in the 3rd quarter. Deutsche Bank AG now owns 581,601 shares of the biopharmaceutical company’s stock worth $14,395,000 after buying an additional 3,626 shares in the last quarter. Hudson Bay Capital Management LP grew its position in Agios Pharmaceuticals by 3.8% in the third quarter. Hudson Bay Capital Management LP now owns 270,000 shares of the biopharmaceutical company’s stock worth $6,682,000 after acquiring an additional 10,000 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in Agios Pharmaceuticals by 478.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 50,504 shares of the biopharmaceutical company’s stock valued at $1,125,000 after acquiring an additional 41,768 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Agios Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,469 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 5,040 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Agios Pharmaceuticals by 3.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,934 shares of the biopharmaceutical company’s stock worth $867,000 after purchasing an additional 1,437 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.